Duskin-Bitan H, Shimon I (2020) Prolactinomas in males: any differences? Pituitary 23(1):52–57

Article  PubMed  Google Scholar 

Rudman Y, Duskin-Bitan H, Richter I, Tsvetov G, Masri-Iraqi H, Akirov A et al (2023) Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men. Andrology 11(7):1398–1407

Article  CAS  PubMed  Google Scholar 

Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290

Article  PubMed  Google Scholar 

Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19(12):722–740

Article  PubMed  Google Scholar 

Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85(9):3053–3057

CAS  PubMed  Google Scholar 

Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH et al (2002) Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 5(4):243–246

Article  PubMed  Google Scholar 

De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A et al (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf) 64(3):307–313

Article  PubMed  Google Scholar 

Karavitaki N, Dobrescu R, Byrne JV, Grossman AB, Wass JA (2013) Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin Endocrinol (Oxf) 79(2):217–223

Article  CAS  PubMed  Google Scholar 

Sehemby M, Lila AR, Sarathi V, Shah R, Sankhe S, Jaiswal SK et al (2020) Predictors of chronic LH-Testosterone Axis suppression in male Macroprolactinomas with Normoprolactinemia on Cabergoline. J Clin Endocrinol Metab. ;105(12)

Rudman Y, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I (2022) Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25(6):882–890

Article  CAS  PubMed  Google Scholar 

Al Dahmani KM, Almalki MH, Ekhzaimy A, Aziz F, Bashier A, Mahzari MM et al (2022) Proportion and predictors of Hypogonadism Recovery in men with Macroprolactinomas treated with dopamine agonists. Pituitary 25(4):658–666

Article  CAS  PubMed  Google Scholar 

Shimon I, Benbassat C (2014) Male prolactinomas presenting with normal testosterone levels. Pituitary 17(3):246–250

Article  CAS  PubMed  Google Scholar 

Auriemma RS, Galdiero M, Vitale P, Granieri L, Lo Calzo F, Salzano C et al (2015) Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology 101(1):66–81

Article  CAS  PubMed  Google Scholar 

Burke WT, Penn DL, Castlen JP, Donoho DA, Repetti CS, Iuliano S et al (2019) Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J Neurosurg 133(2):321–328

Article  PubMed  Google Scholar 

Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G et al (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 53(1):53–60

Article  PubMed  Google Scholar 

Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904–909

Article  CAS  PubMed  Google Scholar 

Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB et al (2008) Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 93(11):4245–4253

Article  CAS  PubMed  Google Scholar 

Millar RP, Sonigo C, Anderson RA, George J, Maione L, Brailly-Tabard S et al (2017) Hypothalamic-pituitary-ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women with Chronic Amenorrhea. J Endocr Soc 1(11):1362–1371

Article  PubMed  PubMed Central  Google Scholar 

Maiter D (2019) Prolactinomas in men. In: Tritos NA, Klibanski A (eds) Prolactin disorders: from Basic Science to Clinical Management. Springer International Publishing, Cham, pp 189–204

Chapter  Google Scholar 

Burlacu MC, Maiter D, Duprez T, Delgrange E (2019) T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 63(2):323–331

Article  CAS  PubMed  Google Scholar 

Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM (2015) The association of obesity with sex hormone-binding globulin is stronger than the association with ageing–implications for the interpretation of total testosterone measurements. Clin Endocrinol (Oxf) 83(6):828–833

Article  CAS  PubMed  Google Scholar 

Singh A, Dobs AS (2019) Is it Time to test the Effect of Weight loss on Testosterone? Clin Chem 65(1):48–50

Article  CAS  PubMed  Google Scholar